ArticleBMC cancer2023
Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.Cancer medicine · 2024Trial
- Value of preoperative peripheral blood inflammation markers in predicting prognosis after radical gastric cancer surgery.Scientific reports · 2026Article
- The Effectiveness of Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) and Model for End-Stage Liver Disease (MELD) Score in Predicting Prognosis in Portal Vein Thrombosis, a Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Radiosurgery in Upper Tract Urothelial Carcinoma (UTUC).Cancers · 2026Article
- Radical Nephroureterectomy Pentafecta as a Predictor of Upper Tract Urothelial Carcinoma Outcomes Following Radical Surgery.Annals of surgical oncology · 2026Article
- Machine learning-based integration of systemic immune-inflammation and nutritional signatures for predicting disease-free survival in upper tract urothelial carcinoma: a multicenter study.Frontiers in immunology · 2026Article
- Competing risk analysis for predicting distant metastasis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy: based on a large dataset from a national medical center.World journal of surgical oncology · 2025Article
- Artificial Intelligence and Novel Technologies for the Diagnosis of Upper Tract Urothelial Carcinoma.Medicina (Kaunas, Lithuania) · 2025Review
- Prognostic impact of albumin-bilirubin score in predicting the long-term survival of distal cholangiocarcinoma after radical surgery.World journal of surgical oncology · 2025Article
- Prediction of post‑nephroureterectomy renal function in non‑dialysis upper tract urothelial carcinoma using machine learning with PyCaret and SHAP explanations.Oncology letters · 2025Article
- Blood-, Tissue- and Urine-Based Prognostic Biomarkers of Upper Tract Urothelial Carcinoma.Diagnostics (Basel, Switzerland) · 2024Review
- Review
- A new nomogram for predicting extraurothelial recurrence in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy.Frontiers in oncology · 2024Article
- Evergene: an interactive webtool for large-scale gene-centric analysis of primary tumours.Bioinformatics advances · 2024Article
- Imaging in Upper Tract Urothelial Carcinoma: A Review.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThis study aimed to evaluate the clinical significance of a novel systemic immune-inflammation score (SIIS) to predict oncological outcomes in upper urinary tract urothelial carcinoma(UTUC) after radical nephroureterectomy(RNU).
methodThe clinical data of 483 patients with nonmetastatic UTUC underwent surgery in our center were analyzed. Five inflammation-related biomarkers were screened in the Lasso-Cox model and then aggregated to generate the SIIS based on the regression coefficients. Overall survival (OS) was assessed using Kaplan-Meier analyses. The Cox proportional hazards regression and random survival forest model were adopted to build the prognostic model. Then we established an effective nomogram for UTUC after RNU based on SIIS. The discrimination and calibration of the nomogram were evaluated using the concordance index (C-index), area under the time-dependent receiver operating characteristic curve (time-dependent AUC), and calibration curves. Decision curve analysis (DCA) was used to assess the net benefits of the nomogram at different threshold probabilities.
resultAccording to the median value SIIS computed by the lasso Cox model, the high-risk group had worse OS (p<0.0001) than low risk-group. Variables with a minimum depth greater than the depth threshold or negative variable importance were excluded, and the remaining six variables were included in the model. The area under the ROC curve (AUROC) of the Cox and random survival forest models were 0.801 and 0.872 for OS at five years, respectively. Multivariate Cox analysis showed that elevated SIIS was significantly associated with poorer OS (p<0.001). In terms of predicting overall survival, a nomogram that considered the SIIS and clinical prognostic factors performed better than the AJCC staging.
conclusionThe pretreatment levels of SIIS were an independent predictor of prognosis in upper urinary tract urothelial carcinoma after RNU. Therefore, incorporating SIIS into currently available clinical parameters helps predict the long-term survival of UTUC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.